GGrantIndex
← Leaderboards

Guangyong Peng

Washington University

$8,077,871
Attributed
$8,284,121
Total exposure
8
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.6M · FY201225
$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,284,121 · 8

By mechanism

R01$7,042,496 · 5
R21$1,241,625 · 3

Top collaborators

Most similar at Washington University

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos

Research focus

Alzheimer&AposRegulatory T-LymphocyteMediatingOutcome StudyT-LymphocyteMolecularImmunotherapyNovel StrategiesAffectSenescenceCell AgingImmunePublic HealthCellsResponseMalignant NeoplasmsSignal TransductionTumor-DerivedTumor ImmunityIn VivoCancer TherapyPreventTumorLipids

Grant awards (28)

Excessive lipid metabolism in T cell senescence and immunosuppression$388,750
R01 · FY2025 · AI · contact PI
Metabolic Control of T Cell Senescence in Pathogenesis and Immunotherapy of Alzheimer's Disease$380,975
R01 · FY2025 · AG · contact PI
Metabolic Control of T Cell Senescence in Pathogenesis and Immunotherapy of Alzheimer's Disease$388,750
R01 · FY2024 · AG · contact PI
Excessive lipid metabolism in T cell senescence and immunosuppression$388,750
R01 · FY2024 · AI · contact PI
Targeting T Cell Senescence and Dysfunction for Anti-tumor Immunity$1
R01 · FY2024 · CA · contact PI
Metabolic Control of Innate and Adaptive Immunity in Breast Cancer$1
R01 · FY2024 · CA · contact PI
Metabolic Control of Innate and Adaptive Immunity in Breast Cancer$433,609
R01 · FY2023 · CA · contact PI
Targeting T Cell Senescence and Dysfunction for Anti-tumor Immunity$408,718
R01 · FY2023 · CA · contact PI
Metabolic Control of T Cell Senescence in Pathogenesis and Immunotherapy of Alzheimer's Disease$388,750
R01 · FY2023 · AG · contact PI
Excessive lipid metabolism in T cell senescence and immunosuppression$388,750
R01 · FY2023 · AI · contact PI
Metabolic Control of Innate and Adaptive Immunity in Breast Cancer$422,302
R01 · FY2022 · CA · contact PI
Targeting T Cell Senescence and Dysfunction for Anti-tumor Immunity$398,204
R01 · FY2022 · CA · contact PI
Metabolic Control of T Cell Senescence in Pathogenesis and Immunotherapy of Alzheimer's Disease$378,750
R01 · FY2022 · AG · contact PI
Targeting T Cell Senescence and Dysfunction for Anti-tumor Immunity$167,231
R01 · FY2021 · CA · contact PI
Metabolic Control of Innate and Adaptive Immunity in Breast Cancer$93,461
R01 · FY2021 · CA · contact PI
Targeting T Cell Senescence and Dysfunction for Anti-tumor Immunity$346,556
R01 · FY2020 · CA · contact PI
Metabolic Control of Innate and Adaptive Immunity in Breast Cancer$346,556
R01 · FY2020 · CA · contact PI
Role of Senescent T cells in Alzheimer's Disease$285,918
R21 · FY2020 · AG · contact PI
Role of Senescent T cells in Alzheimer's Disease$130,707
R21 · FY2020 · AG · contact PI
Gamma/Delta Treg Cells and Human Breast Cancer$336,158
R01 · FY2019 · CA · contact PI
Gamma/Delta Treg Cells and Human Breast Cancer$346,556
R01 · FY2018 · CA · contact PI
Gamma/Delta Treg Cells and Human Breast Cancer$346,556
R01 · FY2017 · CA · contact PI
Gamma/Delta Treg Cells and Human Breast Cancer$346,556
R01 · FY2016 · CA · contact PI
Gamma/Delta Treg Cells and Human Breast Cancer$346,556
R01 · FY2015 · CA · contact PI
Commitment and Plasticity of Th17 cells and Tregs in the Tumor Microenvironment$187,500
R21 · FY2013 · AI · contact PI
T Regulatory Cells and Neonatal Innate Immunity$187,500
R21 · FY2013 · AI
T Regulatory Cells and Neonatal Innate Immunity$225,000
R21 · FY2012 · AI
Commitment and Plasticity of Th17 cells and Tregs in the Tumor Microenvironment$225,000
R21 · FY2012 · AI · contact PI